NGS analysis with the myeloid panel was repeated, confirming the persistence of mutations in DNMT3A and TET2 observed at the diagnosis of CML, with similar VAF, without additional abnormalities. This evidence concerns the gene DNMT3A and chronic myelogenous leukemia, BCR-ABL1 positive.